CDK4 and mesothelioma: Given that CDKN2A is deleted in approximately 45% of mesothelioma cases [15], palbociclib, a CDK4/6 kinase inhibitor, has been tested for its ability to induce cell-cycle arrest and senescence in mesothelioma [42].